Young man hiking up mountain outside.

GO THE
DISTANCE FOR LONG-TERM OUTCOMES1

SFA Therapy

Drug-Coated Balloons Scatterplot

THINK LONG.

Only IN.PACT™ Admiral™
drug-coated balloon (DCB) shows consistently high patency
in short and long lesions.2

INTERACT WITH CHART
Physician Image

BEST PRACTICES FOR EFFECTIVE SFA LONG-LESION TREATMENT

READ SUPPLEMENT
EndoVascular Today SFA Supplement

Leading experts share the latest on thinking long-term for SFA therapy. 

In.Pact Admiral

For long lesions, one option is 
 better in the long run.


MORE CLINICAL RESULTS

<span style='font-size:46px; line-height:46px;'>89%</span>
 <span style='font-size:24px; line-height:24px;'>The highest primary patency<br>in long lesions at 12 months (28.7 cm)
<sup>2-4</sup>
</span>


<span style='font-size:46px; line-height:46px;'>24%</span>
 <span style='font-size:24px; line-height:24px;'>higher primary patency vs. PTA at 3 years in pivotal trial lesions<sup>5<sup>
</span>


 

PHYSICIAN PERSPECTIVES

Read articles from physician experts on PAD therapy.

VIEW ARTICLES
Physician

JOIN OUR EMAIL LIST

Receive updates and information on our products and therapies.

SIGN UP NOW

GO THE DISTANCE  VESSEL PREP
 PRIOR TO DCB


HawkOne System

DOWNGRADE THE LESION. UPGRADE <br>THE OUTCOME. <br>

Remove the plaque barrier to improve blood flow with the HawkOne™ directional atherectomy system.

SEE HAWKONE IN ACTION

DURABLE. CONSISTENT.
 SAFE.

Reduce interventions and preserve future treatment options with the IN.PACT Admiral DCB 

LEARN HOW
IN.PACT Admiral Drug-Coated Balloon

CONTROLLED DILATATION.

Minimize vessel trauma, reduce dissections, and decrease the need for bailout stenting with the Chocolate™* PTA balloon catheter.

LEARN MORE
1

Three-year results from the IN.PACT Global Study. Tepe G. CIRSE 2018. Long-term results of the IN.PACT SFA randomized Trial. Four-year outcomes: Schneider P. VIVA 2017.

2

IN.PACT™ Admiral™ IFU M052624T001 Rev 1H. Primary patency is defined as freedom from core laboratory-assessed restenosis (duplex ultrasound PSVR ≤ 2.4) or clinically driven target lesion revascularization through 12 months (adjudicated by a clinical events committee blinded to the assigned treatment). Patency per Kaplan-Meier estimates at 12 months (provisional stent rate of 42.5%).

3

Lutonix 035 DCB Instructions for Use BAW1387400r3 (2016).

4

Zeller T, Peeters P, Bosiers M, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. J Endovasc Ther. December 2014;21(6):765-774.

5

Medtronic Data on file. 3-year Outcomes: Schneider et al. Circ Cardiovasc Interv. 2018;11:e005891. Treatment of Drug-Coated Balloons IS Durable to 3 Years in the Femoropopliteal Arteries. PRIMARY PATENCY. Freedom from core laboratory-assessed restenosis (duplex ultrasound PSVR ≤ 2.4) and clinically driven target lesion revascularization through 12, 24, and 36 months (adjudicated by a Clinical Events Committee blinded to the assigned treatment). The primary patency was calculated based on Kaplan-Meier estimates.

™* Third party brands are trademarks of their respective owners.